Meropenem/Vaborbactam and Cefiderocol as Combination or Monotherapy to Treat Multi-Drug Resistant Gram-Negative Infections: A Regional Cross-Sectional Survey from Piedmont Infectious Disease Unit Network (PIDUN)

Meropenem/vaborbactam (MV) and cefiderocol were recently approved by the Food and Drug Administration and European Medicines Agency and are among the most promising antibacterial in treatment regimens against multi-drug resistant (MDR) gram-negative bacilli. A survey with close-ended questions was p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lupia, Tommaso, Corcione, Silvia, Shbaklo, Nour, Montrucchio, Giorgia, De Benedetto, Ilaria, Fornari, Valentina, Bosio, Roberta, Rizzello, Barbara, Mornese Pinna, Simone, Brazzi, Luca, De Rosa, Francesco Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624317/
https://www.ncbi.nlm.nih.gov/pubmed/36278643
http://dx.doi.org/10.3390/jfb13040174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624317/
https://www.ncbi.nlm.nih.gov/pubmed/36278643
http://dx.doi.org/10.3390/jfb13040174

Ejemplares similares